Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 10/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | MTOR | P42345 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30407537 | 1.00 | FASN (0.33) | FASNPDE10APIK3CAMTORKDM4E | |
| SCHEMBL13650611 | 0.79 | MAPKAPK2 (0.39) | FASNKDM4EALDH1A1L3MBTL1OPRM1 | |
| SCHEMBL6267340 | 0.79 | PDE10A (0.31) | PDE10A | |
| SCHEMBL745011 | 0.78 | SMN1; SMN2 (0.35) | PDE10AKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL15167374 | 0.78 | PTPN11 (0.34) | PDE10A | |
| SCHEMBL15180526 | 0.78 | HRH3 (0.42) | PDE10AKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL743942 | 0.77 | OPRM1 (0.47) | OPRM1OPRL1 | |
| SCHEMBL30406892 | 0.77 | OPRM1 (0.36) | FASNKDM4EALDH1A1L3MBTL1OPRM1 | |
| SCHEMBL747572 | 0.77 | OPRM1 (0.36) | FASNKDM4EALDH1A1L3MBTL1OPRM1 | |
| SCHEMBL25190685 | 0.74 | KMT2A (0.33) | PDE10AALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023081665-A1 | COMPOUNDS AS CRR2 MODULATORS | ARIA PHARMACEUTICALS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081666-A1 | COMPOUNDS AS CCR2 MODULATORS | ARIA PHARMACEUTICALS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081666-A1 | COMPOUNDS AS CCR2 MODULATORS | ARIA PHARMACEUTICALS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081665-A1 | COMPOUNDS AS CRR2 MODULATORS | ARIA PHARMACEUTICALS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20170050942-A1 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2017-02-23 | — | — | US | disclosed |
| US-20170050942-A1 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2017-02-23 | — | — | US | disclosed |
| US-20150231114-A1 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | PFIZER (US) | 2015-08-20 | — | — | US | disclosed |
| US-20150231114-A1 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | PFIZER (US) | 2015-08-20 | — | — | US | disclosed |
| US-20140155377-A1 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155377-A1 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2014-06-05 | — | — | US | disclosed |
| US-7576089-B2 | 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION | 2009-08-18 | — | — | US | disclosed |
| US-7576089-B2 | 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors | INCYTE CORPORATION | 2009-08-18 | — | — | US | disclosed |
| EP-1696919-A4 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1565436-A4 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORP (US) | 2007-07-18 | — | — | EP | disclosed |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | INCYTE HOLDINGS CORPORATION | 2006-11-09 | — | — | US | disclosed |
| EP-1696919-A2 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | Incyte Corporation (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050192302-A1 | 3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors | PFIZER INC. | 2005-09-01 | — | — | US | disclosed |
| EP-1565436-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2005060665-A2 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2004050024-A2 | 3-AMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155377-A1 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CCR5, CXCR3 | FASN 2500/4885PDE10A 2040/4885PIK3CA 3379/4885 |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | CCR2, CXCR3, CCR5 | FASN 4167/4885PDE10A 2229/4885PIK3CA 3924/4885 |
| US-20050192302-A1 | 3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors | CCR2, CCR5, CXCR3 | FASN 2684/4885PDE10A 2086/4885PIK3CA 3591/4885 |
| US-20150231114-A1 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CCR5, CXCR3 | FASN 2848/4885PDE10A 2146/4885PIK3CA 3651/4885 |
| US-20170050942-A1 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | CCR2, CCR5, CXCR3 | FASN 2684/4885PDE10A 2086/4885PIK3CA 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.